As CD8+ CTL are the major effectors of anti-tumor immunity, most of the studies of anti-tumor vaccines have focused on the selection of potential tumor antigen peptides that could bind to MHC-I molecules, as these cell surface molecules are the restricting elements for CTLs and are expressed in all cells, thus also in tumor cells. Here, CD8A is linked to neoplasm.